Affimed GmbH

The sponsor demonstrates a concentrated focus on developing innovative immunotherapy approaches for cancer treatment. Their research portfolio emphasizes harnessing the body's immune system to combat malignancies through advanced therapeutic mechanisms. The company's investigational programmes target multiple cancer types, with particular attention to hematological malignancies and solid tumors that have proven resistant to conventional treatment modalities.

• Novel immune cell engager platforms
• Bispecific antibody development
• NK cell-based immunotherapy
• Combination immunotherapy strategies

The therapeutic development strategy encompasses both monotherapy approaches and combination regimens designed to enhance anti-tumor immune responses. Research efforts are directed toward addressing treatment-refractory cancers where existing therapeutic options have demonstrated limited efficacy, representing a significant unmet medical need in oncology.